CREB3 (aa76-87) Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-CREB3 (aa76-87) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CREB3 (aa76-87) |
| Clone | polyclonal |
| Host Species | Goat |
| Reactive Species | human; expected from sequence similarity: human |
| Isotype | n/a |
| Format | antigen affinity purified |
| Size | 0.1 mg |
| Concentration | 100ug specific antibody in 200ul |
| Applications | Peptide ELISA (EIA), Western Blot (WB) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | n/a |
| Immunogen | Immunogen: Peptide with sequence C-HHDHTYSLPRET, from the internal region of the protein sequence according to NP_006359.3. Epitope: Internal region |
| Other Names | [CREB3; cAMP responsive element binding protein 3; LUMAN; LZIP; CREB-3; basic leucine zipper protein; cAMP-responsive element-binding protein 3; cyclic AMP response element (CRE)-binding protein/activating transcription factor 1; cyclic AMP-responsive elem; CREB3; cAMP responsive element binding protein 3; LUMAN; LZIP; CREB-3; basic leucine zipper protein; cAMP-responsive element-binding protein 3; cyclic AMP response element (CRE)-binding protein/activating transcription factor 1; cyclic AMP-responsive element-binding protein 3; leucin zipper proitein; transcription factor LZIP-alpha; CREB3 (aa76-87)], [CREB3; CREB3; LZIP; LUMAN; sLZIP; LZIP; CREB-3; cAMP-responsive element-binding protein 3; N-terminal Luman; Transcriptionally active form] |
| Gene, Accession # | [CREB3], Gene ID: 10488, NCBI: NP_006359.3 |
| Catalog # | MBS423336 |
| Price | $305 |
| Order / More Info | CREB3 (aa76-87) Antibody from MYBIOSOURCE INC. |
| Product Specific References | n/a |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies